2008
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the Treatment of Mood and Anxiety Disorders. CNS Drugs 2008, 22: 761-786. PMID: 18698875, DOI: 10.2165/00023210-200822090-00004.Peer-Reviewed Original ResearchConceptsTreatment of moodAnxiety disordersMultiple molecular actionsOpen-label trialPlacebo-controlled trialAmino acid neurotransmissionCommon adverse effectsLiver function testsAmyotrophic lateral sclerosisVoltage-gated sodium channelsBorderline personality disorderSelf-injurious behaviorStandard therapyIll patientsBipolar depressionFunction testsObsessive-compulsive disorderCase reportGlutamatergic neurotransmissionGlutamate levelsExtracellular glutamateClinical consequencesLateral sclerosisAstrocytic uptakeRiluzole
2006
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder
Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutics 2006, 3: 69-81. PMID: 16490414, PMCID: PMC3593363, DOI: 10.1016/j.nurx.2005.12.006.Peer-Reviewed Original ResearchConceptsGlutamate modulating agentsObsessive-compulsive disorderTreatment of OCDRecent magnetic resonance spectroscopy (MRS) studyTreatment-resistant obsessive-compulsive disorderModulating agentsGlutamate-modulating drugsThalamo-cortical circuitrySerotonin reuptake inhibitorsElevated glutamate levelsCurrent treatment strategiesMagnetic resonance spectroscopy studyCommon psychiatric disordersNovel pharmacotherapeutic agentsAmyotrophic lateral sclerosisNovel therapeutic interventionsFunctional neuroimaging studiesGlutamate hyperactivityComplete remissionReuptake inhibitorsGlutamatergic activityMetabolic hyperactivitySignificant morbidityCase reportCortico-striato